...
首页> 外文期刊>BMC Health Services Research >Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
【24h】

Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study

机译:通过审查药物(药物)在初级保健中预防医院入学:群集的设计随机,控制,多中心药学研究

获取原文

摘要

Background Medication can be effective but can also be harmful and even cause hospital admissions. Medication review or pharmacotherapy review has often been proposed as a solution to prevent these admissions and to improve the effectiveness and safety of pharmacotherapy. However, most published randomised controlled trials on pharmacotherapy reviews showed no or little effect on morbidity and mortality. Therefore we designed the PHARM (Preventing Hospital Admissions by Reviewing Medication)-study with the objective to study the effect of the total pharmaceutical care process on medication related hospital admissions and on adverse drug events, survival and quality of life. Methods/Design The PHARM-study is designed as a cluster randomised, controlled, multi-centre study in an integrated primary care setting. Patients with a high risk of a medication related hospital admission are included in the study with randomisation at GP (general practitioner) level. We aim to include 14200 patients, 7100 in each arm, from at least 142 pharmacy practices. The intervention consists of a patient-centred, structured, pharmaceutical care process. This process consists of several steps, is continuous and occurrs over multiple encounters of patients and clinicians. The steps of this pharmaceutical care process are a pharmaceutical anamnesis, a review of the patient's pharmacotherapy, the formulation and execution of a pharmaceutical care plan combined with the monitoring and follow up evaluation of the care plan and pharmacotherapy. The patient's own pharmacist and GP carry out the intervention. The control group receives usual care. The primary outcome of the study is the frequency of hospital admissions related to medication within the study period of 12 months of each patient. The secondary outcomes are survival, quality of life, adverse drug events and severe adverse drug events. The outcomes will be analysed by using mixed-effects Cox models. Discussion The PHARM-study is one of the largest controlled trials to study the effectiveness of the total pharmaceutical care process. The study should therefore provide evidence as to whether such a pharmaceutical care process should be implemented in the primary care setting. Trial Registration Trial number: NTR 2647
机译:背景技术可以有效,但也可能是有害甚至导致医院入学。药物审查或药物治疗审查通常提出作为防止这些录取和提高药物治疗的有效性和安全性的解决方案。然而,大多数已发表的药物治疗评论的随机对照试验表明对发病率和死亡率没有或几乎没有影响。因此,我们设计了Pharm(通过审查药物预防医院入学) - 目的是研究总药物护理过程对药物相关医院入院以及不良药物事件,生存和生活质量的影响。方法/设计药物研究设计为集群,控制,多中心研究,在集成的初级保养环境中。患有药物相关医院入院的高风险的患者均包含在GP(全科医生)水平的随机化研究中。我们的目标是在每个臂中包含14200名患者,从至少142名药房做法中包含7100名患者。干预包括患者以患者为中心的,结构化的药物护理过程。该过程包括几个步骤,在多次遇到患者和临床医生的情况下是连续的并且发生。该药物护理过程的步骤是药物厌氧,对患者药物治疗的综述,药物护理计划的配方和执行,联合监测和后续评估护理计划和药物疗法。患者自己的药剂师和GP进行干预。对照组接受普通护理。该研究的主要结果是与每位患者12个月的研究期内与药物相关的医院入学频率。二次结果是生存,生活质量,不良药物事件和严重不良药物事件。通过使用混合效应COX模型将分析结果。讨论药学研究是研究总药物护理过程的有效性的最大对照试验之一。因此,研究应提供证据,以证明是否在初级保健环境中实施此类药物护理程序。试用登记试验号码:NTR 2647

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号